Skip to main content

Table 5 Changes in clinical laboratory data during the observation period

From: Clinical advantage and tolerability of ibandronate in hemodialysis patients: a retrospective study

 

Baseline

End of study

P*

Hemoglobin (g/dL)

10.2 ± 1.3

10.1 ± 0.8

0.75

Hematocrit (%)

31.7 ± 3.9

31.2 ± 2.5

0.66

Platelet count (× 104 cells/mm3)

16.2 ± 5.7

16.1 ± 5.3

0.86

Blood urea nitrogen (mg/dL)

57.0 ± 13.3

60.7 ± 11.8

0.31

Serum creatinine (mg/dL)

9.6 ± 2.2

10.0 ± 2.5

0.55

Serum sodium (mEq/L)

137.7 ± 2.2

137.0 ± 2.4

0.09

Serum potassium (mEq/L)

4.8 ± 0.6

5.2 ± 0.9

0.08

Serum chloride (mEq/L)

107.1 ± 2.4

107.0 ± 2.0

0.93

Serum calcium (mEq/L)

8.8 ± 0.6

8.8 ± 0.7

0.84

Serum inorganic phosphorus (mEq/L)

5.2 ± 1.1

5.2 ± 1.5

0.99

Aspartate transaminase (U/L)

11.8 ± 4.1

9.4 ± 3.0

0.03

Alanine aminotransferase (U/L)

8.6 ± 2.8

6.7 ± 2.6

< 0.01

Alkaline phosphatase (U/L)

278.8 ± 102.1

265.2 ± 111.6

0.34

Lactate dehydrogenase (U/L)

176.1 ± 24.1

170.6 ± 35.4

0.41

Total protein (g/dL)

6.2 ± 0.5

6.2 ± 0.6

0.95

Intact PTH (pg/mL)

284.8 ± 224.4

306.1 ± 355.1

0.71

  1. Values represent mean ± standard deviation
  2. PTH parathyroid hormone
  3. *Paired t test (P < 0.05)